

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application:

1-20. (Cancelled)

21. (Currently amended) A composition for regenerating nerves, comprising an agent capable of inhibiting a p75 signal transduction pathway, wherein the agent is a Pep5 polypeptide consisting of the sequence of SEQ ID NO:2, or a sequence ~~consisting of at least 90% homology thereto, derived therefrom by from one to five amino acid substitutions, deletions, and additions~~ which retains the biological activity of Pep5; and

wherein the agent also comprises a PTD domain.

22. (Original) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway is in a form appropriate for delivery to a neuron at a site desired for nerve regeneration.

23. (Canceled)

24. (Withdrawn) A composition according to claim 23, wherein the transduction agent in the p75 signal transduction pathway comprises at least one transduction agent selected from the group consisting of MAG, PKC, IP₃, GT1b, p75, Rho GDI, Rho, p21, and Rho kinase.

25. (Previously presented) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway has the action of inhibition of an interaction between p75 and Rho GDI.

26. (Previously presented) A composition according to claim 21, wherein the agent capable of inhibiting the p75 signal transduction pathway comprises an agent

capable of suppressing or extinguishing an interaction between p75 and Rho GDI, and wherein

the agent capable of inhibiting the p75 signal transduction pathway is present in an amount effective for regeneration.

27. (Currently amended) A composition for regenerating nerves comprising an agent capable of inhibiting a p75 signal transduction pathway, wherein the agent is a Pep5 polypeptide consisting of the sequence of SEQ ID NO:2, or a sequence consisting of at least 90% homology thereto, derived therefrom by from one to five amino acid substitutions, deletions, and additions which retains the biological activity of Pep5;

wherein the agent comprises a PTD domain; and

wherein the composition is suitable for *in vivo* or *in vitro* administration forms.

28-262. (Cancelled)

263. (Previously presented) A kit for regenerating nerves, comprising:

(a) a container comprising a composition according to claim 21 or 27, and

(b) instructions for using the composition of (a).

264. (Previously presented) A medicament for regenerating nerves comprising the composition of claim 21 or 27.

265. (Previously presented) The medicament of claim 264, wherein said medicament is a solid formulation selected from the group consisting of a tablet, pill, capsule, granule, abstract, powder, and suppository.

266. (Previously presented) The medicament of claim 265, wherein said medicament is a liquid formulation selected from the group consisting of a syrup, an injection, a suspension, a solution, and a spray agent.